ERBB2 and breast cancer: As for the molecular subtypes, compared with YBC with HR+/HER2-, those with HR-/HER2+ had the highest risk of LM (OR=4.81, 95% CI 3.42–6.76), followed by HR+/HER2+ and triple-negative BC.